Siao-Yi Wang, M.D., Ph.D.
Assistant Professor
To see if Siao-Yi Wang is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Philosophy of Care
Dr. Wang's philosophy of care is to include the patient and loved ones as a part of the team. Once the goals of the patient have been established, the various options are reviewed in a multidisciplinary manner. Ultimately, the recommended treatment is based on what best fits each individual patient
Clinical Interests
Dr. Wang is a medical oncologist who specializes in aerodigestive malignancies. He specifically offers care for patients with head/neck and thoracic malignancies. His clinical interests include utilizing novel immunotherapies and molecular therapies to provide the most leading-edge treatment for his patients.
Research/Academic Interests
Dr. Wang's research interests are in cancer immunology. He is specifically interested in T-cells and utilizing novel methods to harness their killing ability to fight cancer. He is involved in both laboratory and clinical research, investigating ways to improve adoptive T-cell therapy for malignant diseases.
Division
Hematology and Oncology
Center/Program Affiliation
Undergraduate School
B.A., M.C.B., UC Berkeley, 2002
Medical School
M.D., Ph.D., University of Iowa, 2010
Internship
Internal Medicine, St. Mary's Medical Center, Long Beach, 2012-13
Residency
Internal Medicine, St. Mary's Medical Center, Long Beach, 2013-14
Residency
Internal Medicine, University of Illinois, Chicago, 2014-15
Fellowship
Hematology/Oncology, Loyola University, Illinois, 2015-18
Wang SY, Moore TV, Dalheim AV, Scurti GM, Nishimura MI. Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response. Sci Rep. 2021 Jun 25;11(1):13327. PMID: 34172810
Moore TV, Scurti GM, DeJong M, Wang SY, Dalheim AV, Wagner CR, Hutchens KA, Speiser JJ, Godellas CV, Fountain C, Fleser J, Moudgil T, Thomas M, Murray D, Curti BD, Clark JI, Fox BA, Nishimura MI. HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells. Mol Ther Oncolytics. 2021 Jan 26;20:352-363. PMID: 33614916
Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM. Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors. Lung Cancer (Auckl). 2020 Apr 17. PMID: 32368168
Moore T, Wagner C, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI. Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunol Immunother. 2017 Oct 20. PMID:29052782